- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Urothelial Tract Cancer - July 2002
National Cancer Institute®
Last Modified: July 1, 2002
- Intracavitary therapy of noninvasive transitional cell carcinomas of the upper urinary tract. A review of the literature.
- Ureteritis cystica presenting as a retractile ureteral polyp.
- Myxoid invasive papillary urothelial carcinoma of the bladder and urethra.
- Upper tract transitional cell carcinoma following cystectomy for bladder cancer.
- [A case of renal pelvic tumor due to phenacetin abuse]
- Transitional cell carcinoma of the renal pelvis in a patient with cyclophosphamide therapy for malignant lymphoma: a case report and
- Primary urethral transitional cell carcinoma in a female.
- [Acute urinary retention caused by urethral polyp]
- Bladder substitution in women.
- [Technical solution for single kidney patients with multiple ureteral neoplasms]
- Prognostic impact of extensive parenchymal invasion pattern in pT3 renal pelvic transitional cell carcinoma.
- [Synchronous presentation of inverted papilloma with transitional carcinoma focus in right kidney pelvis and bladder urothelial carcinoma]
Table of Contents
1
UI - 11598443
AU - Bassi P; Iafrate M; Longo F; Iannello A; Mostaccio G; Ingrassia A;
TI -
Repele M; Tavolini IM
Intracavitary therapy of noninvasive transitional cell carcinomas of the
upper urinary tract. A review of the literature.
SO - Urol Int 2001;67(3):189-94
AD - Department of Urology, University of Padua Medical School, Via
Giustiniani, 2, I-35128 Padua, Italy. bassipf@unipd.it
Noninvasive (stages Ta, T1, Tis) transitional cell carcinomas of the
upper urinary tract are suitable for a conservative therapeutic
approach. Intracavitary therapy (alone or as adjuvant treatment) has
recently been proposed and successfully used by some authors. Even
though bacillus Calmette-Guerin is the most frequent agent employed,
chemotherapeutic drugs, such as mitomycin C and thiotepa, have also been
successfully used. The current information available in the literature
is therefore reviewed. According to the data available, intracavitary
therapy is a worthwhile conservative therapeutic option for noninvasive
upper urinary tract urotheliomas with acceptable side effects. For this
reason it may be included in the routine urological armamentarium.
2
UI - 12050527
AU - Parker B; Patel B; Coffield KS
TI -
Ureteritis cystica presenting as a retractile ureteral polyp.
SO - J Urol 2002 Jul;168(1):195-6
AD - Division of Urology, Department of Surgery, Scott and White Memorial
Hospital and Clinic, Temple, Texas 76708, USA.
3
UI - 11827423
AU - Chetty R; Clarke B
TI -
Myxoid invasive papillary urothelial carcinoma of the bladder and
urethra.
SO - Pathology 2001 Nov;33(4):515-8
AD - Department of Anatomical Pathology, Nelson R. Mandela Medical School,
University of Natal, Durban, South Africa. chettyr@nu.ac.za
An unusual case of myxoid transitional cell (urothelial) carcinoma
occurring in a 75-year-old man is presented. The primary tumour in the
bladder, which was treated by partial cystectomy, consisted of areas of
conventional high grade invasive (into the lamina propria) papillary
urothelial carcinoma with separate myxoid areas. The latter component
accounted for 25% of the tumour. Nine months later, the patient
presented with haematuria once again, and a tumour was detected in the
urethra. This was excised and histological examination showed only
myxoid tumour without any overlying dysplasia or obvious epithelial
differentiation. The myxoid areas were positive for epithelial markers
and negative for all mesenchymal markers. This case highlights an
uncommon variety of papillary urothelial carcinoma that invokes a wide
differential diagnosis. Immunohistochemistry is essential in making the
correct diagnosis.
4
UI - 11684849
AU - Huguet-Perez J; Palou J; Millan-Rodriguez F; Salvador-Bayarri J;
TI -
Villavicencio-Mavrich H; Vicente-Rodriguez J
Upper tract transitional cell carcinoma following cystectomy for bladder
cancer.
SO - Eur Urol 2001 Sep;40(3):318-23
AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain.
PURPOSE: We assessed the incidence of upper urinary tract tumors (UUTTs)
after cystectomy for invasive or superficial transitional cell carcinoma
(TCC) of the bladder. The risk factors, patients' characteristics and
evolution of those who developed UUTTs are analyzed. MATERIALS AND
were performed for TCC of the bladder: in 469 instances (82.5%) due to
invasive tumor (T2-T4), and in 99 cases (17.5%) for superficial tumor
(Ta, T1, Tis). All patients were followed for at least 5 years or until
death. A retrospective study of patients who developed UUTTs has been
performed. A revision of bladder tumor and UUTT characteristics, and the
intervals between both is also evaluated. RESULTS: 26 patients (4.5%)
developed UUTTs: 11 of the 99 patients cystectomized for superficial
TCCs (11.1%); 6 of the 392 patients with primary invasive TCC (1.5%),
and 9 of the 77 (11.6%) patients with invasive tumors and a prior
history of superficial TCC. The interval to the development of UUTT was
higher after cystectomy for superficial tumor. TCCs of the bladder that
subsequently developed UUTTs were high grade in 84%, multifocal in 80%,
or had carcinoma in situ in 65%, tumor in the prostatic urethra in 52%,
and involvement of the distal ureter in 57%. Twenty-two UUTTs (84%) were
located in the calyces or the renal pelvis, 3 were bilateral (11.5%), 14
multiple (58%) and 4 superficial (16%). With a median follow-up time of
18 (range 3-103) months, 14 patients (53.8%) died of tumor, 2 were alive
with disease, 2 were lost for follow-up, and 8 (30%) were alive and free
of disease. CONCLUSIONS: We found that patients cystectomized for
superficial or invasive TCC with a prior history of superficial TCC have
a higher incidence of UUTTs. These cases require follow-up with annual
urography or loopography.
5
UI - 12094713
AU - Kojima K; Tamaki M; Maeda S; Hori T; Nishino Y; Deguchi T
TI -
[A case of renal pelvic tumor due to phenacetin abuse]
SO - Hinyokika Kiyo 2002 May;48(5):293-6
AD - Department of Urology, Toyota Memorial Hospital.
A 65-year-old female had been taking analgesics containing phenacetin,
because of severe headaches since 1958. The total dose of phenacetin
that she had taken was calculated to be 8.0 kg. She visited the
department of urology in our hospital in August, 1999 complaining of
gross hematuria. A solid mass was detected in her left renal pelvis on
the abdominal computed tomographic (CT) scan. Under the diagnosis of a
left renal pelvic tumor, nephrouretectomy was performed in September,
1999. Histopathological diagnosis was grade 2 transitional cell
carcinoma. Interstitial nephritis was also observed. Our case is the
twenty-second report of an urinary tract tumor associated with
phenacetin abuse in Japan.
6
UI - 12094715
AU - Shiga Y; Suzuki K; Tsutsumi M; Ishikawa S
TI -
Transitional cell carcinoma of the renal pelvis in a patient with
cyclophosphamide therapy for malignant lymphoma: a case report and
literature review.
SO - Hinyokika Kiyo 2002 May;48(5):301-5
AD - Department of Urology, Hitachi General Hospital.
Cyclophosphamide is considered to be a bladder carcinogen and there are
many reports of secondary bladder cancer, while only a few cases of
upper urothelial cancer have been described. A 59-year-old man, who had
received cyclophosphamide therapy for malignant lymphoma, was suffering
from gross hematuria and consulted our institute. Computerized
tomography (CT), intravenous pyelography (IVP) and retrograde
pyelography (RP) revealed a left renal pelvic tumor. Urinary cytology
showed class V and radical left nephroureterectomy was performed.
Histopathological diagnosis of the left renal pelvic tumor was
transitional cell carcinoma, invading the renal parenchyma. He is free
from recurrence eight months after surgery. To our knowledge, this is
the third case of cyclophosphamide-induced upper urothelial carcinoma
reported in Japan, and the twelfth reported in the English literature.
7
UI - 11851627
AU - Yang SS
TI -
Primary urethral transitional cell carcinoma in a female.
SO - BJU Int 2001 Dec;88(9):985
8
UI - 11490719
AU - Chepurov AK; Krivoborodov GG; Raksha AP; Malenko VP; Shvarts PG
TI -
[Acute urinary retention caused by urethral polyp]
SO - Urologiia 2001 Mar-Apr;(2):45-7
A polyp of the prostatic part of the urethra is a rare pathological
finding. A 20-year-old male visited our clinic with acute urinary
retention. Ultrasound investigation, x-ray and endoscopic examinations
revealed a polyp of the prostatic urethra. The polyp was resected by
Ho-YAG laser. The resection resolved the urinary retention. The
histopathological diagnosis was fibroepithelial polyp.
9
UI - 12084241
AU - Doherty A; Burkhard F; Holliger S; Studer U
TI -
Bladder substitution in women.
SO - Curr Urol Rep 2001 Oct;2(5):350-6
AD - Department of Urology, University Hospital Berne, Anna Seiler-Haus,
CH-3010 Berne, Switzerland. fiona.burkhard@insel.ch
Bladder substitution in women with transitional cell carcinoma (TCC) is
not a universally accepted procedure. There are many concerns, one of
which is the potential risk of metachronous and synchronous urethral
transitional cell carcinoma involvement. Another concern is that voiding
dysfunction may be more frequent than in male patients. The numbers of
female patients who have had this procedure are still small, and
follow-up data are relatively brief. Thus, the true role for orthotopic
bladder substitution in the female is still being evaluated. This paper
reviews the data on this type of surgery in women, with emphasis on
urethral TCC risk and on voiding dysfunction. Early results from a
number of institutions are encouraging, particularly in correctly
selected patients. Based on more than 15 years experience in an albeit
small number of patients, we believe that if there is a functional
external sphincter and tumor margins can be safely cleared, this form of
surgery offers patients the best opportunity to preserve quality of life
following cystectomy.
10
UI - 11822068
AU - Meliani E; Stefanucci S; Corvino C; Semi S; Lapini A; Carini M
TI -
[Technical solution for single kidney patients with multiple ureteral
neoplasms]
SO - Arch Ital Urol Androl 2001 Dec;73(4):205-8
AD - U.O. Urologia, Ospedale S. Maria Annunziata, Firenze, Italia.
When ureteral length is extensively compromised, preservation of the
kidney without recurring to external urinary diversion may be attempted
by various techniques. The choice depends on the extension and
localization of the defect. We report a technique solution performed in
a patient with multiple ureteral tumors and solitary kidney. A 70-years
old underwent TURB for superficial bladder cancer and right
nephroureterectomy for upper urinary tract tumor. He was admitted for
hematuria and renal failure which need a percutaneous nephrostomy.
Urography and pielo-RMN showed multiple and irregular defects of
proximal left ureter. We performed a left ureterectomy with ureteral
substitution by tailored and retroperitonealized ileal segment with
simultaneous ileal bladder augmentation. The six months follow-up
including serum creatinine, sonography, urodynamic evaluation, urinary
cytology, excretory urogram and pielo-RMN shows good results. Ureteral
replacement with ileum is indicated only for extensive ureteral diseases
in which ureteroneocystostomy or vesical Psoas hitch and/or Boari
bladder flap are not feasible. With particular attention to surgical
aspects as tailoring ileum (to improve propulsion of urinary bolus,
limit the absorbing surface area and decrease mucus formation) and the
use of an ileal segment longer than 15 cm (to prevent reflux) and with
an accurate patient selection, we think that this procedure can assure
satisfactory results also in difficult cases.
11
UI - 12115347
AU - Yoshimura K; Arai Y; Fujimoto H; Nishiyama H; Ogura K; Okino T; Ogawa O
TI -
Prognostic impact of extensive parenchymal invasion pattern in pT3 renal
pelvic transitional cell carcinoma.
SO - Cancer 2002 Jun 15;94(12):3150-6
AD - Department of Urology, Kurashiki Central Hospital, Kurashiki, Okayama,
Japan.
BACKGROUND: Pathologic T3 renal pelvic transitional cell carcinoma
exhibits various patterns of invasion. The authors investigated the
prognostic impact of three patterns of invasion of pT3 renal pelvic
transitional cell carcinoma. METHODS: Of 212 patients who underwent
surgery for renal pelvic transitional cell carcinoma, 70 with pT3
disease were eligible for the main analyses. The candidate predictors of
prognosis included patient age, gender, lesion laterality, tumor grade,
perioperative cisplatin-based systemic chemotherapy, lymph node
involvement, vascular involvement, and patterns of invasion. Invasion
patterns were classified as fat invasion, ductal involvement, or
parenchymal invasion. RESULTS: Mean postoperative followup was 33.5
months (range, 1-136 months). On univariate analysis, gender, lymph node
involvement, vascular involvement, and extensive parenchymal invasion
each had a significant impact on the cause specific survival rate. A
multivariate analysis using Cox stepwise regression revealed that
extensive parenchymal involvement was the strongest prognostic predictor
(P = 0.0004, hazard ratio = 5.59). Lymph node involvement (P = 0.0175,
hazard ratio = 3.14) and gender (P = 0.0361, hazard ratio = 2.42) were
other weaker predictors. Statistically, pT3 disease without extensive
parenchymal invasion had a prognosis similar to that of lower stage
disease, and pT3 disease with extensive parenchymal invasion had a
prognosis similar to that of pT4 disease. CONCLUSIONS: Extensive
parenchymal invasion has a strong prognostic impact in renal pelvic
transitional cell carcinoma. pT3 disease should be subclassified into
two separate entities, that with and that without extensive parenchymal
invasion, in view of prognosis. Copyright 2002 American Cancer Society.
12
UI - 11803783
AU - Cuesta Alcala JA; Caballero Martinez MC; Amat Villegas I
TI -
[Synchronous presentation of inverted papilloma with transitional
carcinoma focus in right kidney pelvis and bladder urothelial carcinoma]
SO - Actas Urol Esp 2001 Nov-Dec;25(10):750-4
AD - Servicio de Urologia, Hospital de Navarra, Pamplona.
We report a case with synchronous presentation of inverted papilloma
(I.P) and transitional cell carcinoma of the right renal pelvis (pT2G1)
associated to urothelial carcinoma on left lateral wall of the bladder
(T1G2). Urothelial inverted papilloma is an uncommon, generally benign
tumor that account for 2.2% of all urothelial tumors. Although the
preferred location is the bladder (90%), above all in trigone and
bladder neck, also can be located at the UUT "upper urinary tract"
(7-8%) and urethra (3%). A close follow-up is recommended after
conservative therapy, mainly endoscopic procedure, due to likelihood of
recurrence and synchronous or metachronous association with transitional
cell carcinoma.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
